Manba Finance clears ₹99.99 Cr preferential issue in 2026

Key development and why it matters

Manba Finance Ltd. has moved closer to an equity fundraise through a preferential allotment, after a sequence of exchange filings around a board meeting scheduled for September 22, 2026. The company first informed exchanges about the trading window closure and the agenda to consider an increase in authorised share capital and a preferential allotment of equity shares and or warrants to promoters and non-promoters. Later disclosures indicated the board approved a preferential issue of securities aggregating up to ₹99.99 crore.

Preferential allotments can materially affect a listed company’s capital structure. For existing shareholders, the central questions are dilution, pricing, and the intended use of proceeds. In Manba Finance’s case, the fundraise plan has been linked to growth targets for FY27 and the need to maintain capital buffers as the loan book expands.

Trading window closure and compliance disclosures

Manba Finance informed the exchange that the trading window for directors, promoters, designated persons, connected persons and their immediate relatives would remain closed from September 4, 2026. The closure is scheduled to continue until 48 hours after the conclusion of the board meeting on September 22, 2026.

Such trading window closures are standard governance actions around price-sensitive events, including capital raising proposals. The company’s exchange communication was tagged as “Trading Window-XBRL,” indicating it was made through the structured filing format.

Board meeting agenda: capital increase and preferential allotment

The company disclosed that the board meeting on September 22, 2026 was convened to consider:

• Increasing the authorised share capital and altering the Memorandum of Association
• Issuing equity shares and or share warrants by way of preferential allotment on a private placement basis to promoters and non-promoters

At the time of the meeting intimation, no issue size or pricing details were stated in that particular notice. However, later updates provided specifics on the approval.

Board approval: ₹99.99 crore issue at ₹135

Subsequent information indicated Manba Finance’s board approved a preferential issue of securities aggregating up to ₹99.99 crore. The issue involves equity shares and warrants to be issued at ₹135 each to promoters and public (non-promoters).

The company also approved an increase in authorised share capital from ₹55 crore to ₹65 crore. An authorised capital increase is typically required to ensure the company has sufficient headroom to issue fresh shares and or convert warrants into equity.

How the fundraise ties to Manba Finance’s FY27 growth plan

Manba Finance has outlined a plan to raise around ₹100 crore through a preferential share issue by September or October 2026. The stated objective is to support an aggressive expansion in assets under management (AUM), with management targeting 35% to 40% AUM growth in FY27.

The company’s growth plan is expected to be supported by diversification into personal loans, top-up loans, and secured MSME lending. For an NBFC, faster AUM growth often increases the need for incremental equity to support leverage and capital adequacy requirements, alongside funding through borrowings.

Capital adequacy context: CRAR trend cited

The company’s capital planning has been framed against an observed decline in capital adequacy as the balance sheet expanded. Manba Finance cited that its capital adequacy ratio (CRAR) diluted from 29.81% in FY25 to 24.40% as of June 30, 2026.

While the ratio remained well above minimum regulatory thresholds in the disclosed figures, the change indicates that growth consumed part of the capital buffer. The preferential issue is positioned as a step to maintain headroom for scaling operations.

Recent corporate actions: AGM, dividend, and record date

Manba Finance announced that its 30th Annual General Meeting is scheduled for September 26, 2026, to be held through Video Conferencing and or Other Audio-Visual Means. The company also recommended a final dividend of ₹0.25 per equity share for the financial year ended March 31, 2026, subject to shareholder approval.

The company disclosed a record date of Friday, September 18, 2026 for the final dividend. Separately, the provided market data indicated the stock’s dividend yield at 0.75.

Financial reporting and disclosures referenced by the company

The Board of Directors approved the unaudited financial results for Q1 FY27 on July 27, 2026. The company stated that statutory auditors Krshna & Associates conducted a limited review pursuant to Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company also confirmed compliance with Regulation 54 through a Security Cover Certificate and reported no deviations in the utilization of issue proceeds under Regulation 52(7) and 52(7A). In addition, Manba Finance published the audio recording of its Q1 FY27 earnings conference call held on July 28, 2026.

Funding mix background: debt issuances and liabilities

Manba Finance has previously highlighted efforts to diversify and enlarge its liability franchise in FY26, with borrowings raised of ₹1,265 crore during the year (as stated in the provided information). In earlier periods, the company also received board approval to issue debt securities worth up to ₹200 crore through private placement.

The provided background also notes that the company allotted Non-Convertible Debentures (NCDs) worth ₹25 crore through private placement, comprising 2,500 secured, rated, listed, redeemable NCDs with a face value of ₹1,00,000 each, carrying a 10.95% annual interest rate payable monthly. The NCDs had an allotment date of September 24, 2025 and a maturity date of October 20, 2027.

Market snapshot cited in the disclosures

The material shared with the update included key market data points for Manba Finance:

• Close price shown near ₹137 on September 21
• Current price referenced at ₹137, with another quote indicating ₹136.73 as of September 21, 2026
• Market capitalisation shown as ₹681 crore

These figures provide context, but the preferential allotment pricing and structure remain the primary inputs for assessing dilution and any shift in the shareholder base.

Key facts table

Market impact: what investors typically track next

The immediate market relevance of the board-approved preferential issue is the expected equity dilution and the potential change in promoter and non-promoter holdings, depending on allotment sizes and warrant conversion. The disclosed issue price of ₹135 creates a clear reference point for investors comparing the preferential terms with prevailing market prices around the announcement.

For an NBFC targeting 35% to 40% AUM growth, equity proceeds can influence growth capacity by supporting capital adequacy and enabling additional borrowing. Investors also tend to watch for follow-on disclosures such as the final allotment details, regulatory approvals, and timelines for allotment and warrant conversion.

Analysis: why the capital actions fit the operating narrative

Manba Finance’s disclosures tie the equity plan to growth and capital adequacy management. The cited decline in CRAR from FY25 to June 2026 suggests that balance sheet expansion is already consuming buffers, making capital augmentation a logical step if growth continues at the guided pace.

The company’s broader funding actions, including private placement debt approvals and NCD issuances, indicate an ongoing effort to diversify funding sources. In that context, a preferential equity issue can complement borrowings by strengthening the equity base and potentially supporting leverage within internal and regulatory comfort levels.

Conclusion

Manba Finance’s September 2026 filings show a clear sequence from trading window closure to a board agenda on authorised capital and preferential allotment, followed by approval for a ₹99.99 crore issuance at ₹135 and an authorised capital increase to ₹65 crore. The next set of exchange updates, including allotment details and any shareholder-related approvals where applicable, will be key for investors tracking dilution and the company’s FY27 growth funding plan.